Table 6. Toxicity of nimotuzumab plus NAC followed by CCRT with or without AC.
| Adverse events | During the period of NAC | During the period of CCRT | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | |
| White blood cell | 63 | 57 | 45 | 35 | 10 | 131 | 36 | 29 | 9 | 5 |
| Leukocytopenia | 72 | 52 | 41 | 32 | 13 | 132 | 34 | 31 | 10 | 3 |
| Anemia | 180 | 22 | 6 | 2 | 0 | 109 | 55 | 39 | 7 | 0 |
| Thrombocytopenia | 184 | 17 | 6 | 3 | 0 | 147 | 38 | 23 | 2 | 0 |
| Liver function | 198 | 8 | 4 | 0 | 0 | 192 | 15 | 3 | 0 | 0 |
| Renal function | 203 | 7 | 0 | 0 | 0 | 206 | 3 | 1 | 0 | 0 |
| Mucositis | 175 | 27 | 8 | 0 | 0 | 44 | 84 | 73 | 7 | 2 |
| Dermatitis | 210 | 0 | 0 | 0 | 0 | 0 | 138 | 67 | 5 | 0 |
| Diarrhea | 197 | 9 | 3 | 1 | 0 | 202 | 6 | 2 | 0 | 0 |
| Nausea/vomiting | 157 | 29 | 17 | 5 | 2 | 172 | 25 | 12 | 1 | 0 |
Abbreviations: NAC: neoadjuvant chemotherapy. CCRT: concurrent chemoradiotherapy.